Searchable abstracts of presentations at key conferences in endocrinology

ea0003p159 | Genetics | BES2002

Single nucleotide polymorphisms of the beta2-adrenergic receptor (ADRB2) gene and hypertension

Brain N , Tomaszewski M , Lacka B , Charchar F , Wang W , Padhmanaban S , Anderson N , Zukowska-Szczechowska E , Grzeszczak W , Dominiczak A

Objective: Three nonsynonomous SNPs, Arg16Gly, Gln27Glu and Thr164Ile, in the coding region of the ADRB2 gene affect either receptor affinity or trafficking. Their distribution has been shown to differ significantly in hypertension. We investigated the association of these loci with hypertension in the Silesian Hypertension Study.Methods: Following local ethics approval, 274 unrelated Polish subjects consisting of 146 hypertensives and 128 normotensives ...

ea0003p274 | Steroids | BES2002

What value do cortisol measurements provide in monitoring metyrapone therapy?

Wieringa G , Naing S , Perry L , Anderson J , Wiener K , Burrows G , Warburton R , Kane J , Trainer P

Metyrapone is a potent inhibitor of the conversion of 11-deoxycortisol (11-DOC) to cortisol and is used in the treatment of Cushing's syndrome. This study has assessed the clinical significance of 11-DOC cross-reaction in five serum cortisol assays provided on automated immunoassay analysers. Cross-reaction was determined from the linear regression of increase in measured cortisol against increasing levels of 11-DOC (0, 1590, 4310, 6490, 7040 nmol/L) added to a serum pool. In ...

ea0081p697 | Reproductive and Developmental Endocrinology | ECE2022

Clinical/biochemical characteristics of functioning gonadotroph adenomas in women presenting with ovarian hyperstimulation

Papanikolaou Nikoleta , Coulden Amy , Parker Nina , Lee Sit , Kelly Chris , Anderson Richard , Rees Aled , Cox Jeremy , Dhillo Waljit , Meeran Karim , Al-Memar Maya , Karavitaki Niki , Jayasena Channa

Background: Functioning gonadotroph adenomas (FGA) are rare benign pituitary tumours. Several case reports suggest that FGA may present with features of ovarian hyperstimulation in women. However, a lack of aggregated clinical experience of FGA precludes the meaningful guidance of management in affected women.Methods: Case series of 7 women presenting at different UK sites with FGA induced ovarian hyperstimulation syndrome (OHSS).R...

ea0048oc4 | Oral Communications | SFEEU2017

One year efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion therapy using the Endobarrier device: institution of the UK’s first National Health Service Endobarrier service for type 2 diabetes and obesity

Gupta Piya Sen , Yadagiri Mahender , Irwin Susan , Burbridge Wyn , Gandhi Hardeep , Alden Rachel , Bleasdale John , Fogden Ed , Anderson Mark , Ryder Bob

Introduction: Our institution leads a UK, multicentre, randomised controlled trial (REVISE-Diabesity ISRCTN00151053) investigating the interaction of Endobarrier therapy, a 60 cm endoscopically implanted proximal intestinal liner, with glucagon-like peptide-1 drug therapy.Aims: To evaluate whether acquired experience could translate into establishment of an effective and safe NHS Endobarrier service in patients with diabesity.Metho...

ea0038oc1.1 | Early Career Oral Communications | SFEBES2015

A novel pharmacological approach to target LH and testosterone hypersecretion in women with polycystic ovary syndrome: a randomised, double-blind, placebo-controlled multi-centre randomised clinical trial of the neurokinin B receptor antagonist AZD4901

George Jyothis , Kakkar Rahul , Marshall Jayne , Scott Martin , Finkelman Richard , Ho Tony , McIntosh Stuart , Veldhuis Johannes , Skorupskaite Karolina , Anderson Richard , Webber Lorraine

LH hyper-secretion, driven by increased GnRH pulsatility, underpins excess testosterone secretion – a key clinical feature of PCOS.The kisspeptin-neurokinin B (NKB)-GnRH pathway has emerged as the pivotal regulator of reproduction. We hypothesised that pharmacologic blockade of NKB may address the central pathophysiology of LH hyper-secretion and hyperandrogenism in PCOS. We undertook a randomised, double blind, placebo-controlled multi-centre Phase...

ea0037oc4.2 | Diabetes | ECE2015

Complement factor 5 deficiency leads to defective insulin receptor processing and severe systemic insulin resistance

Kikuchi Takuya , Gutierrez Dario A , Anderson-Baucum Emily K , Bolus W Reid , Hubler Merla J , Palmisano Brian T , McGuinness Owen P , Hasty Alyssa H

Activation of complement factor 5 (C5) produces the anaphylatoxin C5a and the proinflammatory cytolytic complex C5b-9. Recent studies have shown that C5a receptor (C5aR) deficiency leads to improved systemic and white adipose tissue (WAT) insulin sensitivity. This phenotype is considered to be due to the potent inflammatory potential of signalling through C5aR; however, the pleiotropic functions of C5 in inflammation and metabolism remain to be elucidated. We investigated the ...

ea0032oc5.5 | Reproduction | ECE2013

FSHB −211 and FSHR 2039 polymorphisms are associated with serum levels of FSH, AMH and age of pubertal onset in 78 healthy girls: a longitudinal cohort study

Hagen Casper P , Aksglaede Lise , Sorensen Kaspar , Mouritsen Annette , Mieritz Mikkel G , Main Katharina M , Almstrup Kristian , Rajpert-De Meyts Ewa , Anderson Richard A , Juul Anders

Context: Potency of the FSH-pathway varies according to polymorphisms in the promoter of the gene encoding the FSH beta subunit (FSHB −211 G>T, rs10835638) and in the gene encoding the FSH receptor (FSHR 2039 A>G, rs6166). A recent study suggested that carriers of the combination of FSHB GG and FSHR AA had the most reproductive ‘fit’ phenotype (higher serum FSH and a more sensitive FSH receptor). In pre-pubertal girls...

ea0031p291 | Pituitary | SFEBES2013

Is diethylstilboestrol an endocrine disruptor in the developing human fetal testis? Effects of DES exposure using a xenograft approach

Mitchell R T , Anderson R A , van den Driesche S , McKinnell C , MacPherson S , Wallace W H B , Kelnar C J H , Sharpe R M

Context: In rodents, in-utero exposure to the exogenous oestrogen diethylstilboestrol (DES) results in reproductive abnormalities in male offspring. It has been proposed that similar anti-androgenic effects also occur in the human fetal testis following oestrogen exposure.Objective: Determine effects of DES exposure on testosterone production by normally growing human fetal testis xenografts.Design: Human fetal testes (15&...

ea0028oc4.5 | Steroid | SFEBES2012

A novel repressor mechanism regulating fetal Leydig cell steroidogenesis, perturbation of which results in masculinization disorders

van den Driesche Sander , Walker Marion , McKinnell Chris , Scott Hayley , Eddie Sharon , Seckl Jonathan , Drake Amanda , Lee Smith , Anderson Richard , Sharpe Richard

Fetal Leydig cell (LC) dysfunction leads to human male reproductive disorders (‘testicular dysgenesis syndrome’; TDS) that manifest at birth (cryptorchidism, hypospadias) or in young adulthood (low sperm count, testicular germ cell cancer). The factors regulating fetal LC function in early gestation are unknown, but can be disrupted in rats by environmental chemicals (e.g. dibutyl phthalate (DBP)). We identify a novel repressor mechanism that explains this vulnerabil...

ea0028p282 | Reproduction | SFEBES2012

The effects of di(n-butyl) phthalate (DBP) exposure on testis cell development/function in human fetal testis xenografts

Mitchell Rod , Childs Andrew , Anderson Richard , van den Driesche Sander , McKinnell Chris , MacPherson Sheila , Wallace W , Kelnar Chris , Saunders Philippa , Sharpe Richard

Background: Endocrine disruption in the human fetal testis by environmental agents has been proposed as a possible cause of testicular dysgenesis syndrome (TDS) comprising male reproductive disorders such as testicular germ cell tumours (TGCT), cryptorchidism, hypospadias and low sperm counts. Exposure of fetal rats to the widely used plasticizer di(n-butyl) phthalate (DBP) results in a TDS-like syndrome due to a reduction in testosterone production. Whether such effects also ...